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Background: Thrombolysis in the elderly is still a matter of debate. Recently, the Third International
Stroke Trial (IST-3) suggested that recombinant tissue plasminogen activator (rt-PA) improves functional
outcome, without a substantial absolute increase in symptomatic intracranial hemorrhage, even in older
patients. The aim of the current prospective study is to describe safety and functional outcome in a
cohort of patients treated by intravenous rt-PA in an Italian stroke unit “real world setting”.
Methods: All the consecutive patients treated with rt-PA between 2006 and 2010 in an Italian province
with 290,000 inhabitants were enrolled. Total and symptomatic (associated with a 4-point worsening on
the National Institutes of Health Stroke Scale [NIHSS] score) hemorrhages were evaluated, as safety
measures, along with disability (at 3-month modiﬁed Rankin scale) as effectiveness measure.
Results: One hundred and eighty-seven patients were treated with rt-PA; 90 males (48.1%); average age
75.1 (±11.9) years; 79 (42.2%) patients aged 80 years. Patients aged 80 years had a higher NIHSS score
at stroke onset (13.5 vs. 10.9). No signiﬁcant difference was found between patients aged <80 years and
80 years in mortality rate (p ¼ 0.1), total or symptomatic intracranial hemorrhage (p ¼ 0.52 and
p ¼ 0.085, respectively), whereas the 3-month disability was higher in octogenarians (p ¼ 0.004).
Conclusion: Thrombolysis in patients aged 80 years was not associated with signiﬁcantly increased
intracranial hemorrhage. The higher 3-month disability rate observed in octogenarians may be explained
by the more severe stroke and higher poststroke disability. Based on the current, “real world setting”
study, we advocate the need for a randomized clinical trial to better clarify the efﬁcacy and safety of
intravenous thrombolysis for acute ischemic stroke in the elderly.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Thrombolysis in the elderly is still a matter of debate: whether
people aged 80 years may beneﬁt, or are at increased risk of
intracerebral hemorrhage after recombinant tissue plasminogen
activator (rt-PA treatment), remains controversial.1 Indeed, previ-
ous comparative cohort studies, carried out on stroke patients aged
80 years and <80 years treated with intravenous (i.v.) rt-PA,cial interests related to the
t of Neurology, Guglielmo da
aly.
ta).
tric Emergency & Critical Care Meyielded conﬂicting results.2e4 A lower probability of a favorable
outcome and a higher mortality rate in patients aged80 years has
been reported, even if there was no statistically signiﬁcant increase
in the symptomatic intracerebral hemorrhage (SICH) rate.2 How-
ever, a controlled comparison study5 aimed at assessing the effect
of age on rt-PA response in acute ischemic stroke demonstrated
that the association between thrombolysis and improved outcome
was maintained even in the elderly.
Such discrepancy is most likely due to the differences in
methods and baseline populations. First, the deﬁnition of SICH
varies among comparative studies [hemorrhage accompanied by
any decline in neurological status or by a 4-point National Institutes
of Health Stroke Scale (NIHSS) deterioration, according to European
Cooperative Acute Stroke Study (ECASS) criteria6]. Second, olderdicine. Published by Elsevier Taiwan LLC. All rights reserved.
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lihood of preexisting disability, and a poorer functional ischemic
stroke outcome.7,8 Third, the percentage of octogenarians, who
usually represent about 37% of all ischemic stroke populations,9 is
only 12e31% in cohort studies,10 suggesting a selection bias.
The results of the Third International Stroke Trial (IST-3)11 have
recently been published: that is, to date, the only randomized,
controlled trial to have investigated into the beneﬁts and safety of
thrombolysis in the elderly. The IST-3 was carried out by random-
izing 3,035 patients (1,617 i.e., 53%, were 80 years) to rt-PA
treatment versus placebo within a 6-hour time frame. According
to the IST-3 results, the beneﬁt of thrombolysis did not seem to be
diminished in elderly patients. However, this trial was not designed
ad hoc to unravel this speciﬁc issue, but to clarify outcome and
safety of thrombolysis in a wider range of patients previously
excluded from treatment with rt-PA.
A subsequent meta-analysis12 reported that the beneﬁt of
thrombolysis in the elderly was similar to that observed in patients
aged<80 years, especially when treatedwithin 3 hours of symptom
onset.
This study aimed to evaluate the safety and effectiveness of
thrombolysis, in terms of total and symptomatic intracranial hem-
orrhage and disability, respectively, at 3 months, in a large single-
center “real world setting” cohort of patients, aged 80 years and
<80 years, treated consecutively with i.v. thrombolysis for ischemic
stroke in an Italian hospital in Piacenza, from 2006 to 2010.
2. Participants and methods
2.1. Study design and participants
This is a prospective, single-center, cohort study, carried out in
the neurology unit (NU) of the Guglielmo da Saliceto Hospital in
Piacenza, the administrative center of a northern Italian province
with about 289,875 inhabitants, covering a territory of 111,940 km.2
Guglielmo da Saliceto Hospital is the main Italian Public Health
Care System Hospital in this province (“District Hospital”, with 529
beds). The study enrolled all the consecutive stroke patients treated
by rt-PA between 2006 and 2010.
2.2. Procedures
The province of Piacenza has four hospitals that admit a total of
about 800 stroke patients per year into their emergency de-
partments (ED), but there is only one NU, in the “District Hospital”,
where thrombolysis is performed by six general and two cerebro-
vascular neurologists. This NU has 21 beds (including 4 stroke-
dedicated beds), and a yearly admission rate for stroke of about
350 patients.
A territorial network for acute stroke care was set up. During
weekdays, i.e., Monday to Saturday, any patient complaining of
acute neurological dysfunction suggestive of stroke underwent a
computed tomography (CT) scan of the brain and routine labora-
tory tests on admission to any of the four EDs. Patients eligible for
rt-PA were quickly transferred to the NU for neurological exami-
nation and i.v. rt-PA, if they fulﬁlled the ECASS III protocol inclusion
criteria,6 except for age. Exclusion criteria were based on the ECASS
III protocol4 and/or having suffered a previous stroke with a sig-
niﬁcant residual disability [modiﬁed Rankin scale (mRS)  3]. Pa-
tients admitted to any of the four EDs for acute neurological deﬁcit
at night, or on Sundays, were sent directly to the NU for neuro-
logical examination and brain CT scan.
Patients fulﬁlling the aforementioned inclusion criteria were
admitted to the NU and administered rt-PA. The patients' de-
mographic characteristics, medical history, exact stroke timing,neurological examination, blood pressure, glucose level, Glasgow
Coma Scale score, and NIHSS score were recorded in an ad hoc
clinical ﬁle. The mRS,13 NIHSS, and Barthel index at 7 days and at
3months were also noted. Any preexisting functional disability was
also evaluated as dependence in at least one activity of daily living
(ADL), or instrumental activity of daily living (IADL), prior to stroke.
Routine brain CT scan was performed 24 hours after treatment and
whenever there was clinical worsening. Any violations of the set
protocol were reported and taken into account in the statistical
analysis.
2.3. Outcome measures
The effectiveness outcome measure was based on disability at
three months. Patients aged <80 years were compared to those
aged 80 years. The primary endpoint was the proportion of sub-
jects with mRs 1 (no disability) at 3 months; the secondary
endpoint was the proportion of patients with mRs 2 (no or mild
disability). The safety outcome measures were the mortality rate,
the total (TICH) and symptomatic (SICH) intracerebral hemorrhage
rate. Patients aged <80 years were compared to those aged
80 years. The primary endpoint was symptomatic hemorrhage,
deﬁned as the presence of hemorrhagic infarction, or a paren-
chymal hematoma, associated with a 4-point increase on the NIHSS
score.6 Secondary endpoints were mortality rate and TICH.
2.4. Statistical analysis
Any differences between the two groups (<80 years and
80 years) were evaluated by the Students t test (or Man-
neWhitney U test, when appropriate) and the Chi-square test for
continuous, or categorical variables, respectively. A multivariate
stepwise logistic regression model was adopted to determine the
independent association of signiﬁcant variables for the TICH
outcome. The following covariates were used: age, sex, NIHSS score
at stroke onset, time from stroke onset to treatment, history of
hypertension, diabetes, atrial ﬁbrillation, and previous stroke. Age
was chosen because the primary objective of the study was to
clarify the safety and effectiveness of rt-PA in the octogenarians in a
“real world setting”; the effect of hypertension on TICH was
documented in the echoplanar imaging thrombolytic evaluation
trial (EPITHET) trial14 and some studies revealed an association
between TICH and diabetes, cardioembolism, stroke extension, and
time from stroke onset to rt-PA administration.15
Statistical analysis was performed by SPSS 16.0 for Mac (SPSS
Inc., Chicago, IL, USA). The study protocol was approved by the local
Ethics Committee and all participants gave written informed
consent.
3. Results
From January 2006 to December 2010, a total of 2,331 stroke
patients from the province of Piacenzawere referred to the NU; 187
(8%) patients fulﬁlled the ECASS III protocol criteria6 (8.4% of those
<80 years and 7.5% of those 80 years) and were treated by rt-PA
within 4.5 hours from stroke onset; 90 (48.1%) males and 97
(51.9%) females.
The average age was 75.1 (±11.9), age range 27e97 years; 79
(42.2%) patients were aged 80 years. The demographic charac-
teristics, prevalence of vascular risk factors, NIHSS score at stroke
onset, door-to-needle time, and stroke onset to treatment time in
the study population are shown in Table 1. There was a higher
frequency of prestroke disability, measured by the ADL/IADL
dependence, in at least one activity, in patients aged 80 years
Table 1
The demographics of the study population and of patients aged <80 years compared
to those aged 80 years.
Feature Total sample <80 y group 80 y group p
Average age (yr ± SD) 75.1 (11.9) 67.9 84.9
Females 51.9 40.7 67.1 <0.000
Atrial ﬁbrillation 30.1 18.7 45.6 <0.001
Diabetes 21 27.1 12.7 0.02
Hypercholesterolemia 25.3 31.8 16.5 0.03
Hypertension 66.7 62.6 72.2 0.21
Smoking habit 16.1 19.6 11.4 0.16
Previous TIA/stroke 14.6 15 14.1 1
Anticoagulants 2.7 1.9 3.8 0.65
Antiplatelets 32.8 35.5 29.1 0.43
NIHSS (± SD) 12 (6.14) 10.9 13.5 0.004
Door-to-needle
time (min ± SD)
97.9 (38) 98.7 96.7 0.71
Onset-to-treatment
time (min ± SD)
161.2 (44.28) 160.9 161.7 0.91
Data are presented as % unless otherwise indicated.
NIHSS ¼ National Institutes of Health Stroke Study; SD ¼ standard deviation;
TIA ¼ transient ischemic attack.
P. Immovilli et al.22[20.8% vs. 7.7%; p ¼ 0.01; odds ratio (OR): 3.16; 95% conﬁdence
interval (CI): 1.26e7.91].
3.1. Disability at 3 months
Disability at 3 months in the entire study population and in the
<80 years and 80 years groups is reported in Table 2. A total of 28
participants (35.4%) had no or mild disability (mRS 0e2) in the
group 80 years, compared to 62 (57.4%) in the group <80 years
(p¼ 0.003; OR: 2.51; 95% CI: 1.38e4.57). In the subgroup of patients
with no disability prior to the onset of stroke (153 patients, 62.7%
<80 years and 37.3% 80 years), 22 patients 80 years (38.6%) had
no poststroke disability (mRS 0e1), compared to 56 (58.3%) pa-
tients in the <80 years group (p ¼ 0.02; OR: 2.23; 95% CI:
1.14e4.35).
3.2. Mortality at 3 months
There was a 15.1% overall 3-month mortality rate (Table 2),
without any statistically signiﬁcant difference between patients
aged <80 years and 80 years (p ¼ 0.1; 95% CI: 0.89e4.54).
3.3. Rate of TICH and SICH
There was a 14% rate of TICH (26 patients) in the entire study
population (Table 2), 16.5% (13 patients) in the80 years group and
12.1% (13 patients) in the <80 years group, without any statisticallyTable 2
Proportion (%) and odds ratio of main outcomes at 3 months for patients aged
<80 years compared with those aged 80 years.
Outcome Total
sample
<80 y group 80 y group p OR (95% CI)
No disability
(mRS 0e1)
43 52.3 30.4 p ¼ 0.004 2.52 (1.37e4.64)
No or mild
disability
(mRS 2)
48.4 57.4 35.4 p ¼ 0.003 2.51 (1.38e4.57)
Mortality 15.1 11.2 20.3 p ¼ 0.1 2.01 (0.89e4.54)
TICH 14 12.1 16.5 p ¼ 0.52 1.42 (0.62e3.27)
SICH 3.2 0.9 6.3 p ¼ 0.085 7.16 (0.82e2.57)
CI ¼ conﬁdence interval; mRS ¼ modiﬁed Rankin scale; OR ¼ odds ratio;
SICH ¼ symptomatic intracerebral hemorrhage; TICH ¼ total intracerebral
hemorrhage.signiﬁcant difference between the groups (p ¼ 0.52). There was a
3.2% rate of SICH in the entire sample (6 patients, 5 in the80 years
group and 1 in the <80 years group). Although there was no sta-
tistically signiﬁcant difference between the two groups (p¼ 0.085),
a trend toward a major risk was observed in the 80 years group.3.4. Violations of protocol
Therewere protocol violations in 14 (9%) patients, 6 (6.7%) in the
<80 years group and 8 (11.9%) in the80 years group (p¼ 0.27; 95%
CI: 0.63e5.76). All violations were due to rt-PA administration after
4 hours and 30 minutes; however, the maximum time from
symptom onset to treatment was 4 hours and 42 minutes.3.5. Multivariate analysis
A logistic regression analysis was performed on TICH because
the very few patients presenting with SICH were poorly represen-
tative (Table 3). A statistically signiﬁcant correlation was observed
between the NIHSS score prior to treatment and TICH (p ¼ 0.02).4. Discussion
The results of the recent randomized controlled trial IST-311 and
a meta-analysis12 on rt-PA for acute stroke suggest that i.v.
thrombolysis seems to be both effective and relatively safe in those
aged 80 years; consequently, age alone should no longer be
considered a barrier to treatment. Furthermore, recent studies
indicate that intravenous rt-PA within 4.5 hours represents a cost-
effective intervention for acute ischemic stroke in most patient
subgroups and is a good economic value versus no treatment.16,17
A noteworthy ﬁnding of our study is that the 3-month disability
rate was higher in patients aged 80 years receiving i.v. throm-
bolysis for ischemic stroke. This seems to be in line with a worse
outcome of i.v. thrombolysis in elderly patients, as reported bymost
comparative cohort observational studies.2 Conversely, the recent
IST-3 study11 suggests that age does not have a negative effect on
beneﬁt. However, some factors should be taken into consideration,
because as major confounders could minimize rt-PA efﬁcacy when
comparing people aged <80 years and 80 years in open-labeled,
nonrandomized clinical studies.
It is well known that elderly patients do tend to have a worse
poststroke functional outcome than younger patients, a difference
that remains despite adjustment for baseline differences in stroke
risk factors and other comorbidities.7,8,18 Also in the current study,
the NIHSS mean score at stroke onset was signiﬁcantly higher in
patients 80 years, in agreement with previous ﬁndings7,18,19 that
disability after stroke is higher in the elderly even in the absence of
rt-PA treatment not only because of age, but also because of theTable 3
Multivariate analysis for the total intracerebral hemorrhage
outcome.
Variable p
Age 0.38
Sex 0.22
Hypertension 0.10
Atrial ﬁbrillation 0.09
Diabetes 0.17
Previous TIA/stroke 0.99
Onset-to-treatment time 0.95
NIHSS at stroke onset 0.02
NIHSS ¼ National Institutes of Health Stroke Study;
TIA ¼ transient ischemic attack.
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more frequent medical complications in the acute phase.
Furthermore, some degree of disability prior to stroke onset was
more frequently observed in the elderly patients in our study, as
might be expected. However, in the subgroup without preexisting
disability, the 3-month functional poststroke outcome was poorer
in the group 80 years, as was the case for the entire study group;
therefore, the presence/absence of preexisting disability did not
seem to signiﬁcantly affect the thrombolysis outcome in those
80 years.
Somewhat surprisingly, the statistical analysis carried out in the
IST-3 study,11 based on the adjusted effect of treatment on the
primary outcome between patients aged <80 years or 80 years,
seemed to demonstrate a greater (p ¼ 0.029) beneﬁt of thrombol-
ysis in patients 80 years. However, about 44% of the patients aged
80 years (726 of 1617) were given i.v. rt-PA within 3 hours,
compared to only 8.6% of those aged <80 years (123/1,418), a dif-
ference that bears a higher clinical relevance. Indeed, the more
favorable time frame of rt-PA administration in the elderly is most
likely to be responsible for the apparently greater beneﬁt obtained
by treatment in this group, whereas it turned out that the time to
randomization signiﬁcantly affected the primary outcome in the
statistical analysis (0e3 hours: adjusted OR ¼ 1.64 in favor of
treatment).
A total of 3,035 patients from 156 centers were enrolled into the
IST-3 study11 over an 11-year period (277 patients per year, average
1.7 patients/center/y). Furthermore, all the patients with a clear
indication for rt-PA were treated according to local guidelines and
were excluded from the study: these selection criteria may well
explain why this study enrolled a higher proportion of elderly
people thanwhat is normally encountered in clinical practice and a
very low average number of patients per center per year.2e9
Another noteworthy ﬁnding of our study is that there was no
difference either in mortality rate or in the TICH/SICH rate between
the two age groups, in agreement with some previous studies20,21
and with the IST-3 death rate at 6 months. However, there was
an evident trend toward a higher frequency of symptomatic hem-
orrhage in the elderly. Such a trend may suggest that although the
elderly are not more prone to hemorrhage after rt-PA than younger
patients, they do run a higher risk of becoming symptomatic after
hemorrhage, due to premorbid conditions/treatments and/or
stroke severity/subtype, or reduced neuronal reserve.
Something that should not be underestimated in this study is
that it was carried out in a “real world” setting, as another funda-
mental question is the reproducibility of the results achieved in
randomized controlled trials in everyday routine, where the se-
lection of stroke patients, based on more restrictive criteria, makes
the cohorts more homogeneous and generally younger than in
clinical practice. Moreover, although there were some protocol vi-
olations, they were similar in patients aged <80 years and
80 years and were, therefore, not signiﬁcant.
We are also aware of some methodological shortcomings of the
study that should be taken into consideration: ﬁrst of all, the
population reported is small andwas collected in a single-center, so
it could be poorly representative of the elderly population in other
settings. Furthermore, the design was observational prospective,
did not compare elderly people treated or not treated with rt-PA,
and was not randomized. Indeed, caution is always wise when
analyzing the safety and efﬁcacy of a treatment through this type of
nonrandomized, noncontrolled study, as the numerous biases and
confounders may render any conclusion unreliable. Hence the
design of the current study only makes it possible to formulate a
hypothesis about a good safety and efﬁcacy of thrombolysis for
acute ischemic stroke in the elderly, but a randomized clinical trial
is mandatory to conﬁrm such hypothesis. We welcome the datafrom the ongoing Italian Thrombolysis in Elderly Stroke Patients in
Italy open-label, randomized trial,22 which has been speciﬁcally
tailored to address the use of thrombolysis within 3 hours in the
elderly stroke patients, in the hope that it may clarify this impor-
tant issue.
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